Nilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis
- PMID: 39634983
- PMCID: PMC11615558
- DOI: 10.7759/cureus.72952
Nilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis
Abstract
Nilotinib, a tyrosine kinase inhibitor (TKI) used in patients of chronic myeloid leukemia (CML), has been known to cause atherosclerosis and arterial stenosis as a rare complication of long-term or high-dose therapy. Patients in this group are more likely to have coronary or peripheral artery disease; intracranial involvement is comparatively uncommon. Furthermore, studies on nilotinib-induced ischemia in Indian populations are scarce. Here, we present a case of ischemic stroke in a patient on long-term nilotinib treatment who, prior to treatment, had no risk factors for stroke. He presented with subacute symptoms of ataxia, motor and sensory deficit, and a raised low-density lipoprotein. MRI revealed multifocal arterial stenosis, as well as areas of infarction and hypoperfusion in the left cerebral hemisphere. Nilotinib therapy was immediately stopped; the patient was treated with dual antiplatelets, statins, and physiotherapy, and he had no major focal deficits on discharge. However, this case serves as a good reminder that even for patients considered to be largely safe from cardiovascular adverse events, regular monitoring of cardiovascular parameters is important so that timely preventive action can be initiated if necessary.
Keywords: chronic myeloid leukemia (cml); drug-induced stroke; long term chemotherapy; multifocal intracranial atherosclerosis; nilotinib; vascular adverse effects; young stroke.
Copyright © 2024, Sibal et al.
Conflict of interest statement
Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures


References
-
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P. Am J Hematol. 2011;86:533–539. - PubMed
-
- Clinical cardiac safety profile of nilotinib. Kim TD, le Coutre P, Schwarz M, et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366654/ Haematologica. 2012;97:883–889. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources